EcoDrugPlus

Cathepsin K

Ensembl ID : ENSPCOG00000022303
Gene Symbol: CTSK
4 Cross references
240 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cathepsin S

Ensembl ID : ENSPCOG00000015772
Gene Symbol: CTSS
4 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cell Division Cycle 7

Ensembl ID : ENSPCOG00000022992
Gene Symbol: CDC7
4 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Checkpoint Kinase 1

Ensembl ID : ENSPCOG00000020333
Gene Symbol: CHEK1
4 Cross references
177 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Checkpoint Kinase 2

Ensembl ID : ENSPCOG00000025787
Gene Symbol: CHEK2
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholecystokinin A Receptor

Ensembl ID : ENSPCOG00000022459
Gene Symbol: CCKAR
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholecystokinin B Receptor

Ensembl ID : ENSPCOG00000015365
Gene Symbol: CCKBR
4 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSPCOG00000013215
Gene Symbol: CHRM1
4 Cross references
101 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSPCOG00000008486
Gene Symbol: CHRM2
4 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSPCOG00000013773
Gene Symbol: CHRM4
4 Cross references
184 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSPCOG00000001166
Gene Symbol: CHRNA3
4 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSPCOG00000017991
Gene Symbol: CHRNA4
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).